Is the cinnamon I buy at the supermarket the same as 'true cinnamon'?

Almost certainly not. Most cinnamon sold in Australian supermarkets is cassia (commonly Cinnamomum burmannii or C. aromaticum), not Ceylon cinnamon (C. verum). They taste similar but differ in their chemical profiles — particularly in coumarin content, which is substantially higher in cassia varieties.

Do cinnamon supplements sold in Australia need TGA approval?

Cinnamon-containing products making therapeutic claims must be listed or registered on the Australian Register of Therapeutic Goods (ARTG) and carry an AUST L or AUST R number. Listed complementary medicines have their safety and quality assessed by the TGA, but efficacy is not independently verified before listing. Sponsors must hold evidence supporting any permitted indications they use.

What is cinnamaldehyde and why does it matter?

Trans-cinnamaldehyde is the primary volatile constituent in cinnamon bark essential oil, typically making up the majority of the oil fraction. It's what gives cinnamon its characteristic aroma and is the compound most often used as a marker in standardised extracts. Much of the laboratory research into cinnamon's biological activity has focused on cinnamaldehyde, though concentrated essential oils behave very differently to whole-bark culinary spice.

Is it safe to take high-dose cinnamon supplements long-term?

This is a question for a healthcare practitioner, not a label. At culinary doses, cinnamon is a widely consumed food ingredient with a long history of safe use. At higher supplemental doses — particularly from cassia-type extracts, which carry higher coumarin levels — there are potential concerns that European and Australian regulatory bodies have flagged, particularly for people with liver sensitivities or those taking other medicines. No supplement decision of this kind should be made without professional advice.

How does cinnamon research relate to terpene or cannabinoid science?

There's a genuine point of overlap: cinnamon essential oil contains terpenes including beta-caryophyllene, a sesquiterpene that has been studied for its affinity at CB2 receptors in the endocannabinoid system. The dietary amounts present in typical cinnamon use are small, and this isn't a basis for any therapeutic claim — but it illustrates how phytochemical research can cut across plant families in unexpected ways.

Cinnamon: Traditional Use, Constituents and Evidence

By Naomi Ellison · 27 April 2026 · 7 min read

My nan kept a cinnamon stick in a jar on her kitchen windowsill in the Adelaide Hills, and I genuinely couldn't tell you whether she thought of it as a spice or a medicine. Probably both , which, as it turns out, is a very old way to think about it.

Cinnamon has been traded, written about and argued over for roughly four thousand years. That's a long time to accumulate both genuine knowledge and a fair amount of folklore that's been dressed up as science. So let's actually look at what it is, what it contains, and where the research stands.

A brief history of cinnamon as a botanical

The genus Cinnamomum belongs to the Lauraceae family and contains several hundred species, but commerce and tradition have mostly focused on two. Cinnamomum verum (syn. C. zeylanicum), sometimes called Ceylon cinnamon or "true cinnamon", is native to Sri Lanka. Cinnamomum cassia , and its close relatives C. aromaticum, C. burmannii (Korintje) and C. loureiroi (Saigon) , dominates the world market by volume and is what most people in Australia are actually buying off the supermarket shelf, often labelled simply as "cinnamon".

Ancient Egyptian records, Sanskrit texts and Chinese medical literature all document cinnamon's use. It appears in the Ebers Papyrus (c.1550 BCE) and was traded across the Arabian Peninsula long before European merchants understood its origins. In Ayurvedic and Traditional Chinese Medicine frameworks, preparations from the bark were prescribed for a broad range of conditions; a history worth knowing, even if those traditional frameworks don't map neatly onto modern evidence-based medicine.

The bark quills most people recognise are harvested from the inner bark of young coppiced shoots. Ceylon cinnamon rolls into thin, multi-layered scrolls; cassia produces harder, thicker single-layered quills. The essential oil, oleoresins and powdered bark have each been used in different traditional contexts, and modern research has tended to pursue them separately, which matters a lot when you're reading a study and trying to work out what was actually tested.

Key constituents: what's in the bark

The chemistry of cinnamon is reasonably well characterised. The major volatile constituent in the essential oil of most commercial species is trans-cinnamaldehyde, which typically comprises 55–90% of the essential oil fraction and is responsible for that familiar warm, spicy aroma. Ceylon cinnamon oil differs somewhat; it contains a higher proportion of eugenol, a phenylpropanoid also found in cloves.

Beyond the volatile fraction, cinnamon bark contains:

Procyanidins and other polyphenols, particularly the A-type procyanidins, which are less common in other plant sources.
Cinnamate esters; including methyl hydroxy cinnamate.
Coumarin, a naturally occurring lactone present in significant quantities in cassia-type cinnamons and at much lower levels in Ceylon cinnamon. This distinction is toxicologically relevant (see below).
Mucilaginous polysaccharides, which make up a proportion of the water-soluble extract fraction studied in some trials.

The terpene fraction of cinnamon essential oil includes compounds such as linalool, alpha-pinene and beta-caryophyllene, the last of which has been studied as a sesquiterpene with affinity for CB2 receptors, a point of crossover between the spice and cannabinoid research worlds that's genuinely interesting, even if the dietary quantities in cinnamon are modest.

If you want to understand phytomedicine more broadly, cinnamon is actually a decent case study: it contains dozens of identifiable constituents, the relative proportions differ between species and preparations, and the clinical literature has not always been careful about distinguishing which extract; from which species, was used. That's a recurring problem.

What the research explores (and where it falls short)

The bulk of modern research interest in cinnamon has focused on two broad areas: glycaemic biology and antimicrobial activity.

On the glycaemic side, laboratory and animal studies have investigated mechanisms involving insulin receptor signalling and glucose transporter expression. Several randomised controlled trials in humans have followed, with mixed results. A 2013 meta-analysis published in the Annals of Family Medicine found statistically significant differences in fasting glucose measures across trials, but the authors were explicit about heterogeneity in the studies, different species, different doses, different durations, different populations. The short version is: the mechanistic hypotheses are plausible and the lab data is interesting, but the clinical picture is not settled. I'd argue anyone presenting the RCT literature as definitive is reading it too generously.

The antimicrobial work is mostly in vitro; test tube and petri dish studies that look at cinnamaldehyde's effects on bacterial and fungal cultures. That kind of research is useful for hypothesis generation, but in vitro activity does not translate automatically to any meaningful effect in a living system, where bioavailability and pharmacokinetics introduce very different constraints.

Some research has also examined cinnamaldehyde's interactions with the TRPA1 channel, a transient receptor potential ion channel involved in nociception. Again, genuinely interesting mechanistic work that shouldn't be extrapolated into health claims.

The coumarin question

Here's something that gets underplayed in popular coverage of cinnamon. Cassia-type cinnamons, the kind most Australians consume; contain relatively high levels of coumarin, a compound the European Food Safety Authority has flagged as a concern at higher intake levels due to potential hepatotoxicity in sensitive individuals. Ceylon cinnamon contains coumarin at much lower levels, often around 0.017 g/kg compared to figures in the range of 1–12 g/kg reported for cassia varieties.

This doesn't mean a sprinkle on your porridge is a problem. But it's directly relevant to the question of standardised extracts and high-dose supplement use. If someone is consuming concentrated cinnamon extract capsules over extended periods, the species and the coumarin content of the specific product matters enormously.

How cinnamon sits in Australian regulatory frameworks

In Australia, the Therapeutic Goods Administration (TGA) regulates complementary medicines, including herbal preparations containing cinnamon. Products that make therapeutic claims must either be entered on the Australian Register of Therapeutic Goods (ARTG) as a Listed or Registered medicine, or comply with the exemptions under the Therapeutic Goods Act 1989.

Listed complementary medicines, the majority of cinnamon-containing supplements on pharmacy shelves, go through TGA listing (AUST L number) rather than full registration. This means their safety and quality are assessed, but efficacy is not independently verified by the TGA prior to listing. Sponsors are legally required to hold evidence supporting any permitted indications, but consumers don't automatically see that evidence. The TGA's Permitted Indications list constrains what claims can appear on the label, and those claims are generally confined to traditional-use language rather than claims based on clinical trial data.

Good Manufacturing Practice (GMP) requirements apply to all ARTG-listed manufacturers, which is relevant when you're thinking about consistency of extracts. Because the biological activity of a cinnamon product depends on which species was used, which part of the plant, and how the extract was prepared, manufacturing consistency is not a trivial concern.

There is no scheduling restriction on cinnamon itself under the Poisons Standard; it's a food spice used safely at culinary doses across the population. But concentrated therapeutic-level preparations carry the standard caveats around complementary medicines regulation, and anyone considering high-dose supplementation should have that conversation with a healthcare practitioner, not a label.

Cinnamon as a research model for phytomedicine complexity

I keep coming back to cinnamon when I want to explain why phytomedicine research is hard. The plant itself isn't one thing. "Cinnamon" in the literature might be an aqueous extract of C. cassia bark, an essential oil from C. verum leaves, a powdered whole-bark supplement of uncertain species, or an isolated fraction of procyanidins. Each of those is a chemically different intervention, and pooling their results as though they're interchangeable is a methodological problem that haunts the field.

The same challenge applies across botanical research generally, I've written about it in the context of other plants on this site, and it's one reason why single-compound pharmaceutical models sit uneasily alongside multi-constituent plant extracts. The idea of an entourage effect, developed originally in cannabinoid science to describe how constituents might interact within the same plant matrix, is a reasonable conceptual frame to bring to cinnamon research too, even though the specific signalling systems are different.

I spent a wet Saturday last winter going through a 19th-century herbal I'd picked up at a secondhand shop near Stirling; one of those dense, lovingly detailed volumes full of hand-drawn plates. Cinnamon got four pages, including a note on adulteration that could have been written yesterday. The problems researchers are still working through aren't new. The tools are better, but the plant hasn't simplified itself.

Sources

, Naomi Ellison, Botanical & phytomedicine writer

]]>

Common questions

Is the cinnamon I buy at the supermarket the same as 'true cinnamon'?: Almost certainly not. Most cinnamon sold in Australian supermarkets is cassia (commonly Cinnamomum burmannii or C. aromaticum), not Ceylon cinnamon (C. verum). They taste similar but differ in their chemical profiles — particularly in coumarin content, which is substantially higher in cassia varieties.
Do cinnamon supplements sold in Australia need TGA approval?: Cinnamon-containing products making therapeutic claims must be listed or registered on the Australian Register of Therapeutic Goods (ARTG) and carry an AUST L or AUST R number. Listed complementary medicines have their safety and quality assessed by the TGA, but efficacy is not independently verified before listing. Sponsors must hold evidence supporting any permitted indications they use.
What is cinnamaldehyde and why does it matter?: Trans-cinnamaldehyde is the primary volatile constituent in cinnamon bark essential oil, typically making up the majority of the oil fraction. It's what gives cinnamon its characteristic aroma and is the compound most often used as a marker in standardised extracts. Much of the laboratory research into cinnamon's biological activity has focused on cinnamaldehyde, though concentrated essential oils behave very differently to whole-bark culinary spice.
Is it safe to take high-dose cinnamon supplements long-term?: This is a question for a healthcare practitioner, not a label. At culinary doses, cinnamon is a widely consumed food ingredient with a long history of safe use. At higher supplemental doses — particularly from cassia-type extracts, which carry higher coumarin levels — there are potential concerns that European and Australian regulatory bodies have flagged, particularly for people with liver sensitivities or those taking other medicines. No supplement decision of this kind should be made without professional advice.
How does cinnamon research relate to terpene or cannabinoid science?: There's a genuine point of overlap: cinnamon essential oil contains terpenes including beta-caryophyllene, a sesquiterpene that has been studied for its affinity at CB2 receptors in the endocannabinoid system. The dietary amounts present in typical cinnamon use are small, and this isn't a basis for any therapeutic claim — but it illustrates how phytochemical research can cut across plant families in unexpected ways.